Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 1/2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 8NETWORK 4NIH 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × reolysin × Clear all
NCT04445844 2025-04-04

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

Rutgers, The State University of New Jersey

Phase 2 Active not recruiting
25 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03723915 2022-10-05

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

Northwestern University

Phase 2 Terminated
17 enrolled 14 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡